March: New Drug Approvals by the NMPA - February 2024

• Imported drugs:
•  □　Abrocitinib tablets (Brand name: CIBINQO) marketed by Pfizer Inc. - Newly approved for adolescents (12 and above).
• □　Botulinum toxin type A for injection (Brand name: Xeomin) marketed by Merz Pharmaceuticals GmbH
• □　Crovalimab injection (Brand name: Piasky) marketed by Roche Pharma (Schweiz) AG
• □　Entrectinib capsules (Brand name: Rozlytrek) marketed by Roche Pharma (Schweiz) AG - Newly approved for solid tumors that have a NTRK gene fusion in pediatric patients older than 1 month of age.
• □　Susoctocog alfa for injection (Brand name: OBIZUR) marketed by: Takeda Pharmaceuticals U.S.A., Inc.
• □　Teduglutide injection (Brand name: Revestive) marketed by Takeda Pharmaceuticals International AG Ireland Branch
• □　Zinc acetate tablets (Brand name: Nobelzin) marketed by Nobelpharma Co., Ltd.
•  
•  
• Domestic drugs:
• □　Adapalene and clindamycin hydrochloride gel marketed by Zhaoke Ophthalmology
• □　Anagrelide hydrochloride capsules marketed by Heilongjiang Timehome Pharmaceutical Co., Ltd.
• □　Furosemide oral solution marketed by Chengdu Brilliant Pharmaceutical Company
• □　Isosulfan blue injection (Brand name: 博林兰 (Bo Lin Lan)) marketed by Guangdong Hepoer Pharmaceutical Co., Ltd.
• □　ω-3 fish oil medium and long chain fat emulsion/amino acid (16)/glucose (16%) injection marketed by Sichuan Kelun Pharmaceutical Co., Ltd.
• □　Zevorcabtagene autoleucel injection (Brand name: 赛恺泽 (Sai Kai Ze)) marketed by Kaixing Life Science (Shanghai) Co., Ltd.

 

• (Source: BaiPharm)